FLT3 and myeloproliferative disorder: Of 32 clinical trials described in Table 1, 16 focused on patients afflicted with AML or other myeloproliferative disorders and had FLT3 as the main target of inhibition, with treatment regimens relying on first-generation—sorafenib—and second-generation—gilteritinib and quizartinib—inhibitors, and one study utilized the multikinase inhibitor pexidartinib.